Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537373 | 1.00 | GAA (0.55) | GAANR1H2CHRM1CHRM2CHRM3 | |
| SCHEMBL3522986 | 0.84 | CHRM1 (0.45) | GAACHRM1CHRM2CHRM3GPR119 | |
| SCHEMBL3522981 | 0.84 | CHRM1 (0.45) | GAACHRM1CHRM2CHRM3GPR119 | |
| SCHEMBL29242230 | 0.81 | USP30 (0.55) | GAANR1H2NPC1 | |
| SCHEMBL3533984 | 0.80 | GAA (0.68) | GAAKMT2A | |
| SCHEMBL3519594 | 0.80 | CHRM2 (0.48) | CHRM1CHRM2CHRM3GPR119 | |
| SCHEMBL3519589 | 0.80 | CHRM2 (0.48) | CHRM1CHRM2CHRM3GPR119 | |
| SCHEMBL22083469 | 0.79 | KAT2B (0.41) | NR1H2CHRM1CHRM2CHRM3GPR119 | |
| SCHEMBL3522984 | 0.79 | CHRM2 (0.47) | CHRM1CHRM2CHRM3GPR119KMT2A | |
| SCHEMBL6064154 | 0.77 | CHRM1 (0.43) | CHRM1CHRM2CHRM3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2241567-A1 | BICYCLOAMINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | GAA 4207/4885NR1H2 2071/4885CHRM1 135/4885 |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | GAA 4207/4885NR1H2 2071/4885CHRM1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.